{"id":"NCT02644941","sponsor":"Humacyte, Inc.","briefTitle":"Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis","officialTitle":"An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-24","primaryCompletion":"2019-05","completion":"2023-09","firstPosted":"2016-01-01","resultsPosted":"2025-03-30","lastUpdate":"2025-03-30"},"enrollment":355,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Failure","End Stage Renal Disease","Hemodialysis","Vascular Access"],"interventions":[{"type":"BIOLOGICAL","name":"Human Acellular Vessel (HAV)","otherNames":["(regulated as a biological product)"]},{"type":"DEVICE","name":"ePTFE graft","otherNames":[]}],"arms":[{"label":"Human Acellular Vessel (HAV)","type":"EXPERIMENTAL"},{"label":"ePTFE","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.","primaryOutcome":{"measure":"Number of Participants With Loss of Secondary Patency","timeFrame":"12 months post-implantation","effectByArm":[{"arm":"Human Acellular Vessel (HAV)","deltaMin":29,"sd":null},{"arm":"ePTFE","deltaMin":34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":21},"locations":{"siteCount":38,"countries":["United States","Germany","Israel","Poland","Portugal","United Kingdom"]},"refs":{"pmids":["37662589"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":157,"n":177},"commonTop":["Vascular stenosis","Vascular access site thrombosis","Vascular access site pseudoaneurysm","Vascular access site hematoma","Vascular access site hemorrhage"]}}